Press Releases - 2020-05-31

Date	Title	Company
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A	BioMarin Pharmaceutical Inc.
31-May-2020	(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies	Ascentage Pharma
31-May-2020	(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies	Ascentage Pharma